GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Universal Biosensors Inc (ASX:UBI) » Definitions » Debt-to-Asset

Universal Biosensors (ASX:UBI) Debt-to-Asset : 0.12 (As of Sep. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Universal Biosensors Debt-to-Asset?

Universal Biosensors's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was A$0.88 Mil. Universal Biosensors's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was A$2.50 Mil. Universal Biosensors's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was A$29.11 Mil. Universal Biosensors's debt to asset for the quarter that ended in Sep. 2024 was 0.12.


Universal Biosensors Debt-to-Asset Historical Data

The historical data trend for Universal Biosensors's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universal Biosensors Debt-to-Asset Chart

Universal Biosensors Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.07 0.05 0.11 0.17

Universal Biosensors Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.17 0.16 0.12 0.12

Competitive Comparison of Universal Biosensors's Debt-to-Asset

For the Medical Devices subindustry, Universal Biosensors's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Universal Biosensors's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Universal Biosensors's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Universal Biosensors's Debt-to-Asset falls into.



Universal Biosensors Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Universal Biosensors's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Universal Biosensors's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Universal Biosensors  (ASX:UBI) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Universal Biosensors Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Universal Biosensors's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Universal Biosensors Business Description

Traded in Other Exchanges
N/A
Address
1 Corporate Avenue, Rowville, VIC, AUS, 3178
Universal Biosensors Inc is biosensor company in electrochemical cell technology to develop a diverse range of biosensor test strips. The company's platform develops a diverse range of biosensor test strips used in conjunction with point-of-use devices that are used in various industries such as healthcare (point-of-care), wine, food and agriculture. It manufactures and distributes PT-INR coagulation test strips and devices, Xprecia, Stride and Xprecia Prime which are medical devices, Sentia non-medical wine testing products, and Petrackr which is a blood glucose test used in cats and dogs. Geographically, the company generates majority of its revenue from Australia and rest from Americas, Europe and other markets.

Universal Biosensors Headlines

No Headlines